Relationships Among Cerebrospinal Fluid Biomarkers in Dementia of the Alzheimer Type

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Alzheimer Disease and Associated Disorders

• Publication date

  2002-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00002093-200207000-00003PMID 12218644
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease

  2017cited by this paper
• Enzyme-Linked Immunosorbent Assay

  2006cited by this paper
• Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease.

  2000cited by this paper
• Unique Lipoproteins Secreted by Primary Astrocytes From Wild Type, apoE (−/−), and Human apoE Transgenic Mice*

  1999cited by this paper
• Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF

  1999cited by this paper
• Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.

  1999cited by this paper
• Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression

  1999cited by this paper
• Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease.

  1998cited by this paper
• High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

  1998influential reference
• Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease

  1998cited by this paper
• Cerebrospinal Fluid Levels of Amyloid Precursor Protein and Amyloid β-Peptide in Alzheimer’s Disease and Major Depression – Inverse Correlation with Dementia Severity

  1998cited by this paper
• Clinicopathologic correlations of soluble amyloid beta-protein precursor in cerebrospinal fluid in patients with Alzheimer disease and controls.

  1997cited by this paper
• Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease.

  1997cited by this paper
• Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls.

  1997cited by this paper
• Clinical Dementia Rating training and reliability in multicenter studies

  1997cited by this paper
• Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform.

  1996cited by this paper
• Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay*

  1996cited by this paper
• Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease.

  1996cited by this paper
• The neurochemistry of Alzheimer's disease

  1996cited by this paper
• Cerebrospinal protein tau is elevated in early Alzheimer's disease.

  1996cited by this paper
• CSF excitatory amino acids and severity of illness in Alzheimer's disease

  1996cited by this paper
• Assessment of Amyloid β Protein in Cerebrospinal Fluid as an Aid in the Diagnosis of Alzheimer's Disease

  1996cited by this paper
• Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease

  1995cited by this paper
• Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

  1995cited by this paper
• Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type.

  1995cited by this paper
• Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease

  1995cited by this paper
• Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

  1995cited by this paper
• Increased levels of τ protein in cerebrospinal fluid of patients with alzheimer's disease—correlation with degree of cognitive impairment

  1995cited by this paper
• Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease

  1995cited by this paper
• Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease.

  1995cited by this paper
• Decreased levels of soluble amyloid β‐protein precursor are associated with Alzheimer's disease in concordant and discordant monozygous twin pairs

  1994cited by this paper
• Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

  1993cited by this paper
• The Clinical Dementia Rating (CDR)

  1993influential reference
• beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease.

  1993cited by this paper
• The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease.

  1991cited by this paper
• [The neurochemistry of Alzheimer's disease].

  1985cited by this paper

• Novel Biomarkers for Alzheimer's Disease: Plasma Neurofilament Light and Cerebrospinal Fluid

  2024cites this paper
• Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives

  2021cites this paper
• Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and its Clinical Implication in the Management of Alzheimer’s Disease

  2020cites this paper
• Biomarkers of Alzheimer's Disease

  2019cites this paper
• A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression

  2017cites this paper
• Alzheimer’s Disease Cerebrospinal Fluid (CSF) Biomarkers

  2016cites this paper
• CSF tau correlates with CJD disease severity and cognitive decline

  2016cites this paper
• A novel nicotinic mechanism underlies β-amyloid-induced neurotoxicity.

  2015cites this paper
• Expediting the Discovery and Potential Translation of Theranostic Agents for Alzheimer's Disease

  2015cites this paper
• CSF Tau Protein in Alzheimer’s Disease and other Neurological and Psychiatric Diseases

  2015cites this paper
• SOCS3 and SOCS6 are required for the risperidone-mediated inhibition of insulin and leptin signaling in neuroblastoma cells.

  2014cites this paper
• Meta-Review of CSF Core Biomarkers in Alzheimer’s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria

  2014cites this paper
• Cerebrospinal fluid biomarkers of Alzheimer’s disease

  2014cites this paper
• Detecting Oligomeric Beta-Amyloid for the Diagnosis of Alzheimer ’ s Disease

  2013cites this paper
• Potential Blood Biological Markers of Alzheimer's Disease

  2013cites this paper
• Biomarkers for Alzheimer's Disease and Potential Future Directions

  2013cites this paper
• Cerebrospinal fluid biomarkers for neurodegenerative disorders

  2013cites this paper
• Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.

  2013cites this paper
• Aβ in the spinal fluid showing the formation

  2013influential citation
• Evaluation of peptide adsorption-controlled liquid chromatography-tandem mass spectrometric (PAC-LC-MS/MS) method for simple and simultaneous quantitation of amyloid β 1-38, 1-40, 1-42 and 1-43 peptides in dog cerebrospinal fluid.

  2012cites this paper
• Biomarkers for Alzheimer Disease in Cerebrospinal Fluid, Urine, and Blood

  2012cites this paper
• CSF tau and amyloid β42 levels in Alzheimer’s disease—A meta-analysis

  2012cites this paper
• Extracellular Tau Levels Are Influenced by Variability in Tau That Is Associated with Tauopathies*

  2012cites this paper
• Interrelations between CSF Soluble AβPPβ, Amyloid-β 1-42, SORL1, and Tau Levels in Alzheimer's Disease

  2012cites this paper
• Identification of Novel Fluid Biomarkers for Alzheimer's Disease

  2012influential citation
• Neuropsychological predictors of the outcome in non-demented subjects with cognitive complaints

  2012cites this paper
• CSF Biomarkers for Amyloid and Tau Pathology in Alzheimer's Disease

  2011cites this paper
• CSF Biomarkers for Alzheimer's Disease Diagnosis

  2010cites this paper
• Anti-inflammatory therapy and cerebrospinal fluid diagnosis in Alzheimer's disease.

  2010cites this paper
• Defining and labeling disease‐modifying treatments for Alzheimer's disease

  2009cites this paper
• Biomarkers of Alzheimer's disease.

  2009cites this paper
• Increased Total TAU But Not Amyloid-β42; in Cerebrospinal Fluid Correlates with Short-Term Memory Impairment in Alzheimer's Disease

  2009cites this paper
• Study of Cerebrospinal Fluid Tissue Transglutaminase , T-TAU , Amyloid Β 42 in Alzheimer ’ s Disease

  2008cites this paper
• The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients.

  2008cites this paper
• Current state and future directions of neurochemical biomarkers for Alzheimer's disease.

  2007cites this paper
• No association of CSF biomarkers with APOEε4, plaque and tangle burden in definite Alzheimer's disease

  2007cites this paper
• Fibrillar and Oligomeric β‐Amyloid as Distinct Local Biomarkers for Alzheimer's Disease

  2007cites this paper
• No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.

  2007cites this paper
• Fluorescence correlation spectroscopy: ultrasensitive detection in clear and turbid media

  2006cites this paper
• FLUORESCENCE CORRELATION SPECTROSCOPY: ULTRASENSITIVE DETECTION IN CLEAR AND TURBID MEDIA BY ABDEL

  2006cites this paper
• Neuropsychological and behavioural correlates of CSF biomarkers in dementia.

  2006cites this paper
• Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects

  2006cites this paper
• Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.

  2006cites this paper
• Amyloid-beta and tau proteins as biochemical markers of Alzheimer's disease.

  2004influential citation
• Cerebrospinal fluid tau and Aβ42 concentrations in healthy subjects: delineation of reference intervals and their limitations

  2004cites this paper
• Alterations in calcium homeostasis as biological marker for mild Alzheimer's disease?

  2004cites this paper
• Core biological marker candidates of Alzheimer’s disease – perspectives for diagnosis, prediction of outcome and reflection of biological activity

  2004cites this paper
• Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

  2003cites this paper
• Decreased (cid:1) -Amyloid 1-42 and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease

  2003cites this paper
• Dementia Update 2003

  2003cites this paper
• Decreased-Amyloid 1-42 and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease

  2003cites this paper
• Current awareness in geriatric psychiatry. Bibliography.

  2003cites this paper